Adaptimmune Therapeutics plc, of Oxfordshire, U.K., appointed Michael Garone interim chief financial officer.
Alpha Tau Medical Ltd., of Tel Aviv, Israel, appointed Yona Keisari chief scientific officer.
AM-Pharma BV, of Bunnick, the Netherlands, appointed Juliane Bernholz chief operating officer and Kristie Bass vice president clinical operations.
Assertio Therapeutics Inc., of Lake Forest, Ill., appointed David Wheadon to its board.
Arvinas Inc., of New Haven, Conn., appointed Tomasz M. Beer, Adam L. Boxer, Sara Courtneidge, Lennart Mucke, Benjamin G. Neel and Lillian L. Siu to scientific advisory board.
Avidity Biosciences LLC, of La Jolla, Calif., appointed Sarah Boyce president and CEO and to its board.
Biocardia Inc., of San Carlos, Calif., appointed Jim Allen and Andrew Blank to its board.
Biogen Inc., of Cambridge, Mass., appointed Alfred Sandrock executive vice president, research and development, also continuing as chief medical officer. The company also named Alphonse Galdes executive vice president, pharmaceutical operations and technology.
Cure Pharmaceutical Corp., of Oxnard, Calif., appointed Vered Gigi chief scientific officer.
Deciphera Pharmaceuticals Inc., of Waltham, Mass., appointed Matthew L. Sherman executive vice president and chief medical officer.
Genfit SA, of Lille, France, appointed Dean Hum president of Genfit Corp. and Suneil Hosmane head of global diagnostics.
Heron Therapeutics Inc., of San Diego, appointed Kimberly Manhard to its board.
Immunoprecise Antibodies Ltd., of Victoria, British Columbia, appointed Stefan Lang chief business officer.
ITM Isotopen Technologien Muenchen AG, of Garching, Germany, appointed Mona M. Wahba deputy chief medical officer.
Jnana Therapeutics Inc., of Boston, appointed Caroline Stark Beer chief business officer.
Kaleido Biosciences Inc., of Lexington, Mass., appointed Richard Scalzo principal accounting officer and Jean Mixer to its board.
Kitov Pharma Ltd., of Tel Aviv, Israel, appointed Eric K. Rowinsky chair of its board.
Lysogene SA, of Paris, appointed Carole Deffez to its board.
Macrophage Pharma Ltd., of Windsor, U.K., appointed Anker Lundemose to its board.
Mitsubishi Tanabe Pharma America Corp., of Jersey City, N.J., a wholly owned subsidiary of Osaka, Japan-based Mitsubishi Tanabe Pharma Corp., appointed Gustavo A. Suarez Zambrano vice president of medical affairs.
Nektar Therapeutics Inc., of San Francisco, appointed Jonathan Zalevsky chief research and development officer and Gil M. Labrucherie chief operating officer in addition to his role as chief financial officer.
Neovacs SA, of Paris, appointed Vincent Serra CEO.
Neurocrine Biosciences Inc., of San Diego, appointed David W. Boyer chief corporate affairs officer.
Nextcure Inc., of Beltsville, Md., appointed Timothy Mayer chief operating officer.
Nordic Nanovector ASA, of Oslo, Norway, appointed Gabriele Elbl vice president global regulatory affairs.
Ocugen Inc., of Malvern, Pa., appointed Sanjay S. Subramanian chief financial officer.
Osmotica Pharmaceuticals plc, of Bridgewater, N.J., appointed Michael J. DeBiasi to its board.
Precision Biosciences, of Durham, N.C., appointed Nicholas Riddle vice president, financial strategy and investor relations.
Provention Bio Inc., of Oldwick, N.J., appointed Sean Doherty to its board.
Rafael Pharmaceuticals Inc., of Newark, N.J., appointed Wendy McDermott chief people officer.
Relay Therapeutics Inc., of Cambridge, Mass., appointed Jami Rubin to its board.
Retrophin Inc., of San Diego, appointed Peter Heerma chief commercial officer.
Scilex Holding Co., of Palo Alto, Calif., appointed Scott M. Whitcup and Elizabeth Czerepak to its board. Whitcup will serve as lead independent director and Czerepak will chair the audit committee.
Sonoma Pharmaceuticals Inc., of Petaluma, Calif., appointed Amy Trombly interim CEO and John Dal Poggetto chief financial officer.
Teva Pharmaceuticals Industries Ltd., of Jerusalem, appointed Eric Drapé executive vice president, global operations.
Torque Therapeutics Inc., of Cambridge, Mass., appointed John Cox CEO.
Tridek-One, of Paris, appointed Regis Olivier chief financial officer, Jorge Kirilovsky chief scientific officer and Delphine Joyeux chief development officer.
Valeo Pharma Inc., of Montreal, appointed Michel Trudeau to its board.
Vertex Pharmaceuticals Inc., of Boston, appointed Carmen Bozic executive vice president, global medicines development and medical affairs; he will assume the additional role of chief medical officer on April 1, 2020. The company also named Nia Tatsis senior vice president, chief regulatory officer.
Vor Biopharma Inc., of Cambridge, Mass., appointed Sadik Kassim chief technology officer and Tirtha Chakraborty vice president of research.
Xeris Pharmaceuticals Inc., of Chicago, appointed Mark Thierer to its board and audit committee.